Opinion|Videos|March 17, 2025
Rethinking CAR T Timing: Insights on CAR T Efficacy and Patient Selection
Panelists discuss key factors in chimeric antigen receptor T-cell (CAR T) sequencing for relapsed diffuse large B-cell lymphoma, including manufacturing success rates, production turnaround time, and real-world efficacy data. Treatment decisions weigh bridging therapy needs, patient fitness, and center-specific experience with different CAR T products and their reliability.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- How do efficacy outcomes and manufacturing reliability influence your thinking about optimal sequencing of CAR T for patients with relapsed diffuse large B-cell lymphoma?
- What aspects of the real-world manufacturing and treatment experience have most impacted your approach to second-line therapy decisions?
Advertisement
Related to this article
In a phase 2 trial, orelabrutinib plus sintilimab yielded a 60.7% overall response rate in relapsed/refractory primary CNS lymphoma.
Advertisement
Advertisement
Trending on CancerNetwork
1
Predicting Severe Immune-Related Toxicities in Lung Cancer Immunotherapy
2
CD19 CAR T Cell Therapy for Treatment-Refractory Seropositive Rheumatoid Arthritis: A Phase 1 Trial
3
Outpatient Treatment-Related Toxicity After Hospital Discharge Among Patients Receiving Lifileucel for Advanced Melanoma
4
Recapping GI Cancer at ESMO 2026: Standout Data From Phase 1 to Phase 3
5